Hepatitis Drug Development Pipeline Review, 2018

[Total: 0    Average: 0/5]


Latest Report Available at Analytical Research Cognizance Hepatitis Drug Market provides pin-point analysis for changing competitive dynamics and a forward looking perspective on different factors driving or restraining industry growth.


This report provides an overview of the pipeline landscape for hepatitis infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, hepatitis B, hepatitis D and hepatitis E, and features dormant and discontinued products.

Hepatitis refers to inflammation of the liver and is most commonly caused by viral infections. Hepatitis A and E are typically caused by ingestion of contaminated food or water. Symptoms of hepatitis A infection include fatigue, nausea and vomiting, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes.

Access The Complet report @ http://www.arcognizance.com/report/hepatitis-drug-development-pipeline-review-2018

Risk factors include a weakened immune system and use of injected or non-injected illicit drugs. Symptoms of hepatitis E include yellowing of the skin, dark urine, fever, fatigue, joint pain, nausea, a loss of appetite and pain in the abdomen.

Hepatitis B and hepatitis D infection typically occur as a result of contact with infected body fluids. Transmission of hepatitis B can occur via sexual contact, injection drug use or transfusions of contaminated blood and blood products. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes, dark urine, extreme fatigue, nausea, vomitng and abdominal pain.

Hepatitis D infection only occurs in persons previously infected with hepatitis B, as the hepatitis D virus can only replicate in the presence of hepatitis B. The co-infection of hepatitis B and hepatitis D is associated with greater disease severity than hepatitis B infection alone.

Companies operating in this pipeline space include Cadila Healthcare and Chongqing Zhifei Biological Products.

Request for sample copy of  report @ http://www.arcognizance.com/enquiry-sample/74588


– Which companies are the most active within each pipeline?

– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

– What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

– Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Check Discount Offer Before Buying This Report @ http://www.arcognizance.com/discount/74588

Companies Mentioned:

Abivax SA

AiCuris GmbH & Co KG

AIMM Therapeutics BV

Akshaya Bio Inc

Alnylam Pharmaceuticals Inc

Altimmune Inc

Altravax Inc

Amarna Therapeutics BV

Arbutus Biopharma Corp

Arcturus Therapeutics Ltd

Arrowhead Pharmaceuticals Inc

Ascentage Pharma Group Corp Ltd

Assembly Biosciences Inc

Aucta Pharmaceuticals LLC

Beijing Kawin Technology Share-Holding Co Ltd

Beijing Minhai Biotechnology Co Ltd

Benitec Biopharma Ltd

Biological E Ltd

BioStar Pharmaceuticals Inc

Biotron Ltd

Some Points Of Table Of Content:

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7

2 Introduction 8
2.1 Hepatitis Report Coverage 8
2.2 Hepatitis A – Overview 8
2.3 Hepatitis B – Overview 8
2.4 Hepatitis D – Overview 8
2.5 Hepatitis E – Overview 8

3 Therapeutics Development 9
3.1 Hepatitis A 9
3.2 Hepatitis B 12
3.3 Hepatitis D 27
3.4 Hepatitis E 30

4 Therapeutics Assessment 33
4.1 Hepatitis A 33
4.2 Hepatitis B 35
4.3 Hepatitis D 44
4.4 Hepatitis E 49

5 Companies Involved in Therapeutics Development 52
5.1 Hepatitis A 52
5.2 Hepatitis B 54
5.3 Hepatitis D 95
5.4 Hepatitis E 98

6 Dormant Projects 101
6.1 Hepatitis A 101
6.2 Hepatitis B 102
6.3 Hepatitis D 108
6.4 Hepatitis E 108

7 Discontinued Products 109
7.1 Hepatitis B 109

8 Product Development Milestones 110
8.1 Hepatitis B 110
8.2 Hepatitis D 122
8.3 Hepatitis E 131

9 Appendix 132
9.1 Methodology 132
9.2 Coverage 132
9.3 Secondary Research 132
9.4 Primary Research 132
9.5 Expert Panel Validation 132
9.6 Contact Us 133
9.7 Disclaimer 133

About Us:

http://arcognizance.com is an initiation in this new era of “analysis @ thought.” We are on a mission to replace the conventional research programs and give way to the latest methods and information for the organizations. We have created this hub of analytical research papers where you can get an access to the latest and the best research papers coming out from some reliable and budding research houses. After the advent of “new analytics” based on the data collection facilities of big data, the face of “business research facilities” has changed drastically  . With ARC our experts have created a bookshelf where you can check out the research reports that are an outcome of the progression of knowledge in various industry sectors. Alongside you can also check some research papers, market reports, and forecasts that are talking about the “out of the box” developments in the market.

Contact Us:

Matt Wilson,

100 Church street, 8th floor,

Manhattan, New york, 10007

Phone No: +1 (646) 434-7969

Email: sales@arcognizance.com


Leave a Reply